Unraveling the Mystery of Long COVID
Learn about Long COVID and its impact on health.
Stefan Rohner, Rebekka Schnepper, Gunther Meinlschmidt, Rainer Schaefert, Michael Mayr, Katrin Bopp, Andrea Meienberg
― 6 min read
Table of Contents
- What Are the Symptoms?
- How Common is Long COVID?
- What Causes Long COVID?
- The Basel Long COVID Cohort Study (BALCoS)
- Who Can Join?
- What Will Participants Do?
- Timeline for the Study
- How Does Data Collection Work?
- What Will Be Measured?
- The Bigger Picture: A Collaborative Effort
- Potential Biases and Challenges
- Analyzing the Data
- Keeping It Safe: Ethics and Risks
- Inviting Participation
- What’s Next?
- Conclusion
- Original Source
Long COVID, or as some like to call it, the "parting gift" from COVID-19, refers to a set of symptoms that can stick around long after the virus has left the party. While most folks bounce back after a couple of weeks, some find themselves dealing with ongoing issues that can last for months. The World Health Organization says that if you've had COVID-19 and still feel yucky two months later, you might be dealing with what they call "post-COVID-19 condition" or PCC for short.
What Are the Symptoms?
Those who experience PCC can find themselves juggling a mixed bag of symptoms, which can feel like trying to balance laundry on your head. Some of the most common complaints include:
- Fatigue that makes you want to take a nap every hour
- Trouble breathing, even just walking to the fridge
- Sleep disturbances that make you feel like a zombie
- A cough that seems to have taken up permanent residence
- Loss of taste or smell, making meals quite boring
- Chest pain that can feel like a not-so-welcome hug
- Headaches that just won’t quit
How Common is Long COVID?
A bunch of smart folks conducted a review of studies in 2022 and found that between 7.5% and 41% of people who weren’t hospitalized after having COVID-19 experience Long COVID symptoms. For those who were hospitalized, the average rate shot up to about 37.6%. However, because different studies have different methods, it’s a bit tricky to pin down a specific number.
What Causes Long COVID?
While some risk factors for PCC have been identified-like certain virus variants, being female, having high blood pressure, smoking, being overweight, and having other health problems-the exact reasons why some people develop Long COVID are still a bit foggy. Scientists have tossed around a few ideas, including:
- The immune system going a bit haywire
- The body's natural bacteria getting mixed up
- The virus sticking around longer than it should
- The body getting confused and attacking itself
- Problems with tiny blood vessels and blood flow
- Issues in the brain and nerves that control bodily functions
It's clear that there’s a lot to learn about Long COVID, and it's not just a physical thing. Mental Health and emotional factors can also play a big role. Many people dealing with Long COVID say they feel misunderstood, helpless, or just plain frustrated.
The Basel Long COVID Cohort Study (BALCoS)
To tackle the mystery of Long COVID, researchers have launched the Basel Long COVID Cohort Study, or BALCoS for short. This study aims to dig deeper into what PCC really is, how it develops, and how people can manage it. Over a year, Participants will provide a wide range of information about their health, feelings, and experiences.
Who Can Join?
If you're someone who has had COVID-19 and is still feeling unwell, you might be eligible to join the study. The team at the University Hospital Basel is looking for volunteers, whether you've been to their clinic or not. They will ask you to sign a consent form, because, you know, that's just common sense.
What Will Participants Do?
Participants in the study will fill out various surveys and take tests to help the researchers better understand Long COVID. This includes:
- Sociodemographic information (think age, occupation, etc.)
- Clinical data about your health
- Blood tests to get a closer look at what's happening inside your body
- Tests to check your brain function and cognitive abilities
- Questionnaires about your mental health and emotions
- Simple physical performance tests to see how well you move
Timeline for the Study
The recruitment for this study started in February 2023. The research team plans to keep gathering data until at least May 2026, allowing plenty of time to dive into the findings.
How Does Data Collection Work?
When you sign up, you're agreeing to let the researchers gather information from you. This includes your existing medical records and any new data collected during the study. It's like letting your doctor peek into your health diary, but with permission, of course.
Participants have the flexibility to complete assessments in person or remotely, especially if they’re feeling under the weather. If you decide to do it at home, you might miss some hands-on tests, but you’ll still get to share your experiences through online questionnaires.
What Will Be Measured?
Soon after joining the study, participants will start filling out questionnaires about their symptoms and how they affect daily life. They might also take part in physical tests to measure things like how far they can walk in six minutes or how strong their grip is. The researchers will also look at participants' blood samples to gather biological insights.
The Bigger Picture: A Collaborative Effort
The BALCoS study is part of a larger project under the Horizon Europe Long COVID consortium. This group aims to take a holistic view of Long COVID-combining physical, psychological, and social aspects to better understand the condition and find effective ways to help people.
Potential Biases and Challenges
Like any study, there are some things to watch out for. One challenge is that people who feel good enough are more likely to sign up, which could skew the results. The study team is aware of this and intends to analyze data carefully to ensure reliable findings.
Analyzing the Data
The research team will analyze the collected data for patterns and insights to better understand Long COVID. They’ll look at all sorts of information, from mental health questionnaires to physical tests, to see how everything fits together.
Keeping It Safe: Ethics and Risks
The study has been approved by local ethics committees, so participants can rest easy knowing that their involvement is closely monitored. Risks are minimal, and participants even get some cash for their time and effort.
Inviting Participation
The study is designed to reflect the experiences of people dealing with Long COVID from various backgrounds. By gathering diverse insights, the researchers hope to get to the core of what people are experiencing.
What’s Next?
Once the study wraps up, the researchers will publish their findings and share them with the world. They’ll also present the results at conferences and public events to spread awareness about Long COVID and its impacts.
Conclusion
The Basel Long COVID Cohort Study is an important step in understanding Long COVID. By gathering detailed information from participants, researchers aim to shine a light on this condition and help improve the lives of those affected. It’s a journey that requires patience, but with each step, the hope is to find ways to help people reclaim their health and happiness.
Title: The Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort study
Abstract: IntroductionThe recent severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic had a devasting global impact. Many people suffered from coronavirus disease 2019 (COVID-19) and some experienced persistent symptoms interrupting their lives even further. The World Health Organization (WHO) defined the condition of these persistent symptoms as post-COVID-19 condition (PCC). The most prevalent PCC symptoms are fatigue, dyspnea, sleep disturbances, coughing, anosmia and ageusia, chest pain, and headaches. This article describes the protocol of the Basel Long COVID Cohort Study (BALCoS), which aims at fostering understanding of PCC and investigating underlying mechanisms for the development and course of the condition by focusing on participants health status and symptoms with repeated measures over one year. Methods and analysisBALCoS is a prospective single site cohort study. Inclusion criteria are a confirmed PCC diagnosis according to WHO or a subjective attribution of persistent symptoms to PCC, proficiency in German to follow study procedures, and at least 18 years of age. It comprises blood sample collections, standardized neurocognitive and psychometric tests, physical performance measures, and ecological momentary assessments (EMAs). Standardized tests and EMAs are administered at baseline (BL), and at 3-, 6-, and 12-months follow-up. At BL and 12-month follow-up, physical performance and neurocognitive abilities are assessed. Participants provide blood samples at BL. The study is exploratory in nature and a sample size of at least 120 participants is targeted. The study is part of a larger Horizon Europe Long COVID project combining mechanistic, clinical, and intervention studies within an interdisciplinary European research consortium. Ethics and disseminationThe Ethics Commission of Northwest and Central Switzerland approved the study (BASEC-ID: 2023-00359), which is registered at ClinicalTrial.gov (ID: NCT05781893). All participants provide written informed consent. Key results from the study will be published in peer-reviewed journals. Funding DetailsBALCoS is primarily funded by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00094 in the context of the European Unions Horizon Europe research and innovation program under grant agreement No. 101057553.
Authors: Stefan Rohner, Rebekka Schnepper, Gunther Meinlschmidt, Rainer Schaefert, Michael Mayr, Katrin Bopp, Andrea Meienberg
Last Update: 2024-11-04 00:00:00
Language: English
Source URL: https://www.medrxiv.org/content/10.1101/2024.10.29.24316282
Source PDF: https://www.medrxiv.org/content/10.1101/2024.10.29.24316282.full.pdf
Licence: https://creativecommons.org/licenses/by-nc/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to medrxiv for use of its open access interoperability.